📰 Priority Review News
Page 90 - Priority Review News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Priority Review. Real-time updates on events, politics, business and more.
October 19, 2022
/PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB),...
October 14, 2022
Topline results were announced from a large global phase 3 confirmatory study of lecanemab for the treatment of early Alzheimer disease.
October 12, 2022
The FDA has accepted for Priority Review the sBLA for sacituzumab govitecan-hziy for pre-treated HR+/HER2- metastatic breast cancer.
October 12, 2022
LEVERKUSEN (dpa-AFX) - Regeneron Pharmaceuticals, Inc. (REGN) announced the FDA has accepted for Priority Review the supplemental Biologics License Application for EYLEA Injection to treat Retinopathy
October 12, 2022
The Priority Review has been accepted for the sBLA for aflibercept injection for the treatment of retinopathy of prematurity in preterm infants.
October 5, 2022
The FDA has accepted for Priority Review the sBLA for lanadelumab-flyo for prophylaxis to prevent attacks of HAE in patients 2 to <12 years of age.
October 4, 2022
/PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru...
October 4, 2022
/PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co., Ltd. (Nippon Shinyaku; President, Toru...
October 4, 2022
PARAMUS, N.J., Oct. 4, 2022 /PRNewswire/ -- NS Pharma, Inc. (NS Pharma; President, Tsugio Tanaka), a wholly owned subsidiary of Nippon Shinyaku Co...
October 3, 2022
Topline results were announced from a large global phase 3 confirmatory study of lecanemab for the treatment of early Alzheimer disease.